Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.45 |
| ▸ | POLB | P06746 | 1/20 | 0.45 |
| ▸ | HPGD | P15428 | 1/20 | 0.45 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.42 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.42 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.42 |
| ▸ | LMNA | P02545 | 2/20 | 0.42 |
| ▸ | RAF1 | P04049 | 2/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.38 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.38 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.38 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.38 |
| ▸ | ADRB3 | P13945 | 1/20 | 0.38 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.37 |
| ▸ | MAPT | P10636 | 2/20 | 0.37 |
| ▸ | BCHE | P06276 | 1/20 | 0.37 |
| ▸ | ACHE | P22303 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Acetonitrile SCHEMBL28262259 | 0.92 | RAB9A (0.41) | RAB9ASMN1; SMN2POLBHPGDHSD17B10 | |
| SCHEMBL1893211 | 0.81 | ALDH1A1 (0.51) | RAB9ASMN1; SMN2CYP1A2CYP2C9LMNA | |
| SCHEMBL3545255 | 0.80 | KMT2A (0.50) | RAB9AKDM4EMAPT | |
| SCHEMBL13900227 | 0.79 | SMN1; SMN2 (0.54) | RAB9ASMN1; SMN2HSD17B10CYP1A2CYP2C9 | |
| SCHEMBL4736087 | 0.79 | ELANE (0.41) | RAB9ASMN1; SMN2HSD17B10LMNAMAPT | |
| SCHEMBL25407106 | 0.79 | ELANE (0.51) | LMNAKDM4EMAPTBCHEACHE | |
| SCHEMBL25688979 | 0.79 | LMNA (0.53) | RAB9ASMN1; SMN2HPGDCYP1A2CYP2C9 | |
| SCHEMBL27150841 | 0.79 | ALDH1A1 (0.49) | RAB9ASMN1; SMN2HPGDHSD17B10CYP1A2 | |
| Methane SCHEMBL27556274 | 0.78 | KMT2A (0.49) | RAB9AKDM4EMAPT | |
| SCHEMBL27572847 | 0.78 | SMARCA2 (0.40) | RAB9ASMN1; SMN2HPGDHSD17B10KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1567497-B1 | PYRIDINES FOR TREATING INJURED MAMMALIAN NERVE TISSUE | PURDUE RESEARCH FOUNDATION (US) | 2009-09-23 | — | — | EP | claimed |
| EP-3355925-B1 | TREATMENT OF ACUTE TRAUMATIC INJURY | UNIV ROCHESTER (US) | 2024-02-28 | — | — | EP | disclosed |
| CN-106661018-B | Pyrrolo- [2,3-C] pyridine as neurofibrillary tangles imaging agent | 默沙东公司 | 2019-07-19 | — | — | CN | disclosed |
| CN-109153642-A | Indoles and azaindole halogenated allylamine derivatives inhibitors of lysyloxidase and application thereof | 法玛西斯有限公司 | 2019-01-04 | — | — | CN | disclosed |
| CN-108948019-A | Focal adhesion kinase inhibitor and application thereof | 广东东阳光药业有限公司 | 2018-12-07 | — | — | CN | disclosed |
| CN-107848971-A | Heterocyclic compound | 武田药品工业株式会社 | 2018-03-27 | — | — | CN | disclosed |
| CN-106661018-A | Pyrrolo[2,3-c]pyridines as imaging agents for neurofibrilary tangles | 默沙东公司 | 2017-05-10 | — | — | CN | disclosed |
| CN-103038229-B | Heteroaryl compounds and methods of use thereof | SUNOVION PHARMACEUTICALS INC. (US) | 2016-05-11 | — | — | CN | disclosed |
| CN-105228609-A | New transcription factor regulator | CHEN LIN | 2016-01-06 | — | — | CN | disclosed |
| CN-104927742-A | Polyurethane wood structure glue and preparation method thereof | SHANGHAI DONGHE ADHESIVE CO LTD | 2015-09-23 | — | — | CN | disclosed |
| CN-100545160-C | Diamine derivative | DAIICHI SEIYAKU CO (JP) | 2009-09-30 | — | — | CN | disclosed |
| CN-100480249-C | Pyrrolopyridine-2-carboxylic acid amides as glycogen phosphorylase inhibitors | PROSIDION LTD (GB) | 2009-04-22 | — | — | CN | disclosed |
| US-20080132515-A1 | antiviral agents, in particular against cytomegaloviruses; {2-[4-(4-Fluorophenyl)piperazin-1-yl]-3-[3-(trifluoromethyl)phenyl]-3,4-dihydropyrido[3,4-d]-pyrimidin-4-yl}acetic acid hydrochloride | BAYER HEALTHCARE AG (DE) | 2008-06-05 | — | — | US | disclosed |
| CN-1980925-A | Substituted azaquinazolines with antiviral activity | AICURIS GMBH & CO KG (DE) | 2007-06-13 | — | — | CN | disclosed |
| CN-1894238-A | Diamine derivatives | DAIICHI SEIYAKU CO (JP) | 2007-01-10 | — | — | CN | disclosed |
| CN-1856498-A | Thienopyridine and furopyridine kinase inhibitors | ABBOTT LAB (US) | 2006-11-01 | — | — | CN | disclosed |
| CN-1856304-A | Heteroaromatic ureas that modulate the function of the capsaicin-1 receptor (VR1) | MERCK SHARP & DOHME (GB) | 2006-11-01 | — | — | CN | disclosed |
| CN-1826340-A | Pyrrolopyridine-2-carboxylic acid amides as glycogen phosphorylase inhibitors | PROSIDION LTD (GB) | 2006-08-30 | — | — | CN | disclosed |
| CN-1826333-A | Diamine derivatives | DAIICHI SEIYAKU CO (JP) | 2006-08-30 | — | — | CN | disclosed |
| CN-1751025-A | Diamine derivatives | DAIICHI SEIYAKU CO (JP) | 2006-03-22 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080132515-A1 | antiviral agents, in particular against cytomegaloviruses; {2-[4-(4-Fluorophenyl)piperazin-1-yl]-3-[3-(trifluoromethyl)phenyl]-3,4-dihydropyrido[3,4-d]-pyrimidin-4-yl}acetic acid hydrochloride | ZC3HAV1, EIF2AK2, IRF3 | RAB9A 1869/4885SMN1; SMN2 2813/4885POLB 201/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.